BSH 2017 | Current investigations in the use of allogeneic transplant in the treatment of myeloma
Martin Kaiser
• 27 Mar 2017
Martin Kaiser, MD, from the Institute of Cancer Research, London, UK, discusses current investigations in the use of allogeneic transplant in treating myeloma at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Current investigations in the use of allogeneic transplant in the treatment of myeloma involve determining which patients will benefit the most from it. Allogeneic transplant has been commonly used over the past decade, however, novel drugs are being developed that have limited toxicity, as well as improved outcome. This raises the question of the benefit of allogeneic transplant in myeloma patients, and whether its use should continue.
